GANX News and Press, Gain Therapeutics Inc. From 08/11/21

Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer’s Dise...

BETHESDA, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing novel allosteric binding sites on proteins responsible for neurodegenerative diseases an...

BETHESDA, Md., June 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publi...

David Einhorn's 13F stock portfolio value decreased from $1.66B to $1.44B this quarter. Greenlight increased Danimer Scientific and Concentrix while reducing AerCap Holdings, fuboTV, and Resideo Technologies during the quarter. The largest three positions are at ~45% of the portfo...

Point Roberts, WA and Delta, BC - May 28, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Cannabis, Tech, Biotech, Mining, Natural Gas, Water, Wine and Restaura...

BETHESDA, Md., May 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric ...

As the economic recovery gains steam, small-cap stocks are expected to continue leading the way. Substantial progress on the COVID-19 vaccination front and fiscal stimulus packages have raised investors’ confidence in small-cap stocks’ prospects. Consequently, Wall Street expect...

BETHESDA, Md., May 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced that Eric ...

Gain Therapeutics (GANX): Q1 GAAP EPS of -$0.50 misses by $0.29.Revenue of $5.27M (-21.0% Y/Y)Press Release For further details see: Gain Therapeutics EPS misses by $0.29

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collaboration agreement with Zentalis Pharmaceuticals (Nasdaq: ZNTL) to d...